Anzeige
Meldung des Tages: Der US-Öl-Trade, der mit der Geopolitik kollidiert!

CARIS LIFE SCIEN. A News

Aktie
WKN:  A41A14 ISIN:  US1421521071 US-Symbol:  CAI Branche:  Biotechnologie Land:  USA
20,67 $
+0,48 $
+2,38%
17,517 € 18:22:34 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
35,66%
KGV
-
Index-Zuordnung
-

CARIS LIFE SCIEN. A News

08:30 Uhr - PR Newswire
Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
Caris Life Sciences Right-​In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients PR Newswire
08.04.26 - PR Newswire
Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients
Caris Life Sciences Introduces Multimodal AI-​Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients PR Newswire
02.04.26 - PR Newswire
Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies
Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies PR Newswire
31.03.26 - PR Newswire
Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect
Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect PR Newswire
26.03.26 - PR Newswire
Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer
Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer PR Newswire
25.03.26 - PR Newswire
Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026
Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026 PR Newswire
24.03.26 - PR Newswire
Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month
Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month PR Newswire
20.03.26 - PR Newswire
Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients
Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients PR Newswire
16.03.26 - PR Newswire
Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer
Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer PR Newswire
11.03.26 - PR Newswire
Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting
Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting PR Newswire
09.03.26 - PR Newswire
Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer
Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-​Line Therapy Selection and Treatment De-​Escalation in Pancreatic Cancer PR Newswire
26.02.26 - PR Newswire
/C O R R E C T I O N -- Caris Life Sciences/
/C O R R E C T I O N -- Caris Life Sciences/ PR Newswire
26.02.26 - PR Newswire
Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook PR Newswire
24.02.26 - PR Newswire
Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug
Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug PR Newswire
23.02.26 - PR Newswire
Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference
Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference PR Newswire
09.02.26 - PR Newswire
Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26
Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26 PR Newswire
28.01.26 - PR Newswire
Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan
Caris Life Sciences' Real-​World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan PR Newswire
12.01.26 - PR Newswire
Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results
Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results PR Newswire
12.01.26 - PR Newswire
Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect
Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect PR Newswire
05.01.26 - PR Newswire
Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire

Newssuche

Videos

newspaper
07.04.26 +0,99%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »